Matches in SemOpenAlex for { <https://semopenalex.org/work/W2047298889> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W2047298889 abstract "Monoclonal antibodies (mAb) targeting EGFR (epidermal growth factor receptor), cetuximab (Erbitux) and panitumumab (Vectibix), have been approved for the therapy of metastatic colorectal cancer (mCRC). However, the majority of the patients are primarily resistant to EGFR mAbs or become resistant during the treatment. While activating mutations in KRAS have been reported to confer resistance to EGFR mAbs, some recent randomised controlled trials with EGFR mAbs combined to oxaliplatin-based regimens have failed to demonstrate clinical effect even in patients with KRAS wild-type mCRC. We have addressed the effects of EGFR mAbs on the growth of KRAS wild-type and KRAS mutant CRC cell lines in the absence and presence of oxaliplatin. Our observations indicate that while the KRAS mutant genotype is predictive for resistance to single agent EGFR mAbs, the combination of EGFR mAb plus oxaliplatin is not superior to oxaliplatin alone regardless of the KRAS status. However, sequential administration of oxaliplatin prior to EGFR mAb results in a clear additive effect whereas a sequence of EGFR mAb prior to oxaliplatin antagonizes the effect of oxaliplatin. The opposing effects of the two different sequences seem to be independent on both KRAS and BRAF mutation status. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2011 Nov 12-16; San Francisco, CA. Philadelphia (PA): AACR; Mol Cancer Ther 2011;10(11 Suppl):Abstract nr C35." @default.
- W2047298889 created "2016-06-24" @default.
- W2047298889 creator A5039167108 @default.
- W2047298889 creator A5051448120 @default.
- W2047298889 creator A5075680116 @default.
- W2047298889 creator A5077800239 @default.
- W2047298889 date "2011-11-12" @default.
- W2047298889 modified "2023-09-27" @default.
- W2047298889 title "Abstract C35: Response of colorectal cancer cells to combination of EGFR mAbs with oxaliplatin is determined by the sequence of administration." @default.
- W2047298889 doi "https://doi.org/10.1158/1535-7163.targ-11-c35" @default.
- W2047298889 hasPublicationYear "2011" @default.
- W2047298889 type Work @default.
- W2047298889 sameAs 2047298889 @default.
- W2047298889 citedByCount "0" @default.
- W2047298889 crossrefType "proceedings-article" @default.
- W2047298889 hasAuthorship W2047298889A5039167108 @default.
- W2047298889 hasAuthorship W2047298889A5051448120 @default.
- W2047298889 hasAuthorship W2047298889A5075680116 @default.
- W2047298889 hasAuthorship W2047298889A5077800239 @default.
- W2047298889 hasConcept C121608353 @default.
- W2047298889 hasConcept C126322002 @default.
- W2047298889 hasConcept C143998085 @default.
- W2047298889 hasConcept C159654299 @default.
- W2047298889 hasConcept C163864487 @default.
- W2047298889 hasConcept C203014093 @default.
- W2047298889 hasConcept C2777506169 @default.
- W2047298889 hasConcept C2778332735 @default.
- W2047298889 hasConcept C2779438470 @default.
- W2047298889 hasConcept C2779998722 @default.
- W2047298889 hasConcept C2780962732 @default.
- W2047298889 hasConcept C2781187634 @default.
- W2047298889 hasConcept C502942594 @default.
- W2047298889 hasConcept C526805850 @default.
- W2047298889 hasConcept C542903549 @default.
- W2047298889 hasConcept C71924100 @default.
- W2047298889 hasConcept C98274493 @default.
- W2047298889 hasConceptScore W2047298889C121608353 @default.
- W2047298889 hasConceptScore W2047298889C126322002 @default.
- W2047298889 hasConceptScore W2047298889C143998085 @default.
- W2047298889 hasConceptScore W2047298889C159654299 @default.
- W2047298889 hasConceptScore W2047298889C163864487 @default.
- W2047298889 hasConceptScore W2047298889C203014093 @default.
- W2047298889 hasConceptScore W2047298889C2777506169 @default.
- W2047298889 hasConceptScore W2047298889C2778332735 @default.
- W2047298889 hasConceptScore W2047298889C2779438470 @default.
- W2047298889 hasConceptScore W2047298889C2779998722 @default.
- W2047298889 hasConceptScore W2047298889C2780962732 @default.
- W2047298889 hasConceptScore W2047298889C2781187634 @default.
- W2047298889 hasConceptScore W2047298889C502942594 @default.
- W2047298889 hasConceptScore W2047298889C526805850 @default.
- W2047298889 hasConceptScore W2047298889C542903549 @default.
- W2047298889 hasConceptScore W2047298889C71924100 @default.
- W2047298889 hasConceptScore W2047298889C98274493 @default.
- W2047298889 hasLocation W20472988891 @default.
- W2047298889 hasOpenAccess W2047298889 @default.
- W2047298889 hasPrimaryLocation W20472988891 @default.
- W2047298889 hasRelatedWork W1982547746 @default.
- W2047298889 hasRelatedWork W1990237162 @default.
- W2047298889 hasRelatedWork W2000493038 @default.
- W2047298889 hasRelatedWork W2036227968 @default.
- W2047298889 hasRelatedWork W2057822920 @default.
- W2047298889 hasRelatedWork W2067265449 @default.
- W2047298889 hasRelatedWork W2068646313 @default.
- W2047298889 hasRelatedWork W2095169477 @default.
- W2047298889 hasRelatedWork W2145714812 @default.
- W2047298889 hasRelatedWork W2269317413 @default.
- W2047298889 hasRelatedWork W2276445046 @default.
- W2047298889 hasRelatedWork W2469467701 @default.
- W2047298889 hasRelatedWork W2598561509 @default.
- W2047298889 hasRelatedWork W2602019313 @default.
- W2047298889 hasRelatedWork W2605288657 @default.
- W2047298889 hasRelatedWork W2613598102 @default.
- W2047298889 hasRelatedWork W2907854036 @default.
- W2047298889 hasRelatedWork W3112111913 @default.
- W2047298889 hasRelatedWork W3120850158 @default.
- W2047298889 hasRelatedWork W93307583 @default.
- W2047298889 isParatext "false" @default.
- W2047298889 isRetracted "false" @default.
- W2047298889 magId "2047298889" @default.
- W2047298889 workType "article" @default.